Mercado de diagnóstico de cáncer de pulmón de células no pequeñas en América del Norte: tendencias de la industria y pronóstico hasta 2028

Análisis y perspectivas del mercado: mercado de diagnóstico de cáncer de pulmón de células no pequeñas en América del Norte

Se espera que el mercado de diagnóstico de cáncer de pulmón de células no pequeñas de América del Norte gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 13,0% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 1.440,42 millones para 2028.

El cáncer de pulmón de células no pequeñas es una enfermedad en la que se forman células malignas o cancerosas en los tejidos de los pulmones. Hay distintos tipos y cada uno tiene diferentes células cancerosas que crecen y se propagan de distintas maneras. Los tipos de cáncer de pulmón de células no pequeñas (CPCNP) son el carcinoma de células escamosas, el carcinoma de células grandes y el adenocarcinoma. En el carcinoma de células escamosas, el cáncer se forma en las células delgadas y planas que recubren el interior de los pulmones y también se denomina carcinoma epidermoide; el carcinoma de células grandes comienza en varios tipos de células grandes y el adenocarcinoma comienza en las células que recubren los alvéolos y producen sustancias como la mucosidad. Uno de los principales riesgos del cáncer de pulmón de células no pequeñas (CPCNP) es el tabaquismo y los síntomas incluyen tos, que no desaparece, y dificultad para respirar. Se utilizan varias pruebas, como pruebas de diagnóstico por imagen, pruebas moleculares, biopsia y otras, para diagnosticar y examinar el estadio del cáncer. El diagnóstico es importante para identificar la enfermedad a tiempo y poder administrar el tratamiento adecuado.

Los factores que impulsan el crecimiento del mercado de diagnóstico de cáncer de pulmón de células no pequeñas son el aumento del número de población de edad avanzada que es más susceptible al cáncer de pulmón de células no pequeñas, mientras que la alta competencia en el mercado entre los actores locales y globales puede restringir el crecimiento del mercado de diagnóstico de cáncer de pulmón de células no pequeñas.

El informe de mercado de diagnóstico de cáncer de pulmón de células no pequeñas proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de logística de visión artificial, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Alcance y tamaño del mercado de diagnóstico de cáncer de pulmón de células no pequeñas en América del Norte

The North America non-small cell lung cancer diagnostics market is segmented into four notable segments based on the lung cancer type, product, test and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of cancer type, the North America non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cellcarcinoma (LUSC), large cell carcinoma and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the high prevalence of the Lung Adenocarcinoma among all type of non-small cell lung cancer.
• On the basis of product, the North America non-small cell lung cancer diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the availability of the instrument along with advancement in the technology.
• On the basis of test, the North America non-small cell lung cancer diagnostics market is segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to rising need of molecular tests to diagnose non-small cell lung cancer accurately and efficiently.
• On the basis of end user, the North America non-small cell lung cancer diagnostics market is segmented into hospital, clinical laboratories, academics and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.

North America Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis

North America non-small cell lung cancer diagnostics market is analyzed and market size information is provided by country, lung cancer type, products, test and end user.

Countries covered in the North America Non-small cell lung cancer diagnostics market report are US, Canada and Mexico.

US is dominating the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer in U.S.

In U.S., Lung Adenocarcinoma (LUAD) segment is growing due to high prevalence of lung adenocarcinoma among types of non-small cell lung cancer. In Canada, the Lung Adenocarcinoma (LUAD) segment is growing due to rise in need for molecular tests to diagnose non-small cell lung cancer accurately. In Mexico, the Lung Adenocarcinoma (LUAD) segment is growing due to advancements made in technology used in the clinical laboratory to detect molecular abnormalities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Demand of Diagnostic in Medical Setting

North America non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in non-small cell lung cancer diagnostics, and changes in regulatory scenarios with their support for the non-small cell lung cancer diagnostics market. The data is available for historic period 2010 to 2019.

Competitive Landscape and North America Non-Small Cell Lung Cancer Diagnostics Market Share Analysis

North America non-small cell lung cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to non-small cell lung cancer diagnostics market.

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, DrLal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co.,Ltd, Oncimmune, and Biodesix among others.

North America non-small cell lung cancer diagnostics market is fragmented and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

• In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
• In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
• En junio de 2020, F. Hoffmann-La Roche Ltd lanzó el algoritmo automatizado de patología digital, el análisis de imágenes uPath PD-L1 (SP263) para diagnosticar el cáncer de pulmón de células no pequeñas (CPCNP) y mejorar la velocidad y la precisión del tratamiento de diagnóstico.

SKU-64358